help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GOLDBERG, S. V.
Right arrow Articles by NOLAN, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GOLDBERG, S. V.
Right arrow Articles by NOLAN, C. M.

Am. J. Respir. Crit. Care Med., Volume 160, Number 2, August 1999, 508-512

Four-Month, Four-Drug Preventive Therapy for Inactive Pulmonary Tuberculosis

STEFAN V. GOLDBERG, JEFFERY S. DUCHIN, TAMMY SHIELDS, and CHARLES M. NOLAN

Tuberculosis Control Program, Seattle -King County Department of Public Health; and Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington

Standard preventive therapy for inactive pulmonary tuberculosis (TB) is 12 mo of isoniazid. Shorter multiple-drug preventive regimens have been proposed. From December 1993 through January 1996 we evaluated a 4-mo, four-drug regimen of preventive therapy for patients with inactive TB, mostly newly arriving immigrants from countries with high rates of TB and of isoniazid resistance. Fifty-three evaluable patients received a 4-mo regimen of isoniazid, rifampin, ethambutol, and pyrazinamide. We compared their completion rate, side effects, and cost of treatment with those of 108 age-matched patients who had received 12 mo of isoniazid at an earlier time. Sixty-eight percent of patients on the 4-mo regimen completed treatment; 69% of those on the 12-mo regimen completed treatment (p = 0.9393). Side effects were more frequent for the 4-mo regimen (30.2%) compared with 12 mo of isoniazid (11.1%) (p = 0.0027). The cost of providing an uncomplicated, self-supervised regimen was estimated to be almost four times greater for the four-drug regimen compared with isoniazid. These results show that, in terms of compliance, a four-drug, 4-mo regimen had no advantage over standard preventive therapy for persons with inactive pulmonary TB. On the other hand, the shorter, more intensive regimen was associated with more frequent adverse effects and was more costly.




This article has been cited by other articles:


Home page
 Am. J. Public HealthHome page
M. F. Hovell, C. L. Sipan, E. J. Blumberg, C. R. Hofstetter, D. Slymen, L. Friedman, K. Moser, N. J. Kelley, and A. Y. Vera
Increasing Latino Adolescents' Adherence to Treatment for Latent Tuberculosis Infection: A Controlled Trial
Am J Public Health, November 1, 2003; 93(11): 1871 - 1877.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. JASMER, D. C. SNYDER, D. P. CHIN, P. C. HOPEWELL, S. S. CUTHBERT, E. ANTONIO PAZ, and C. L. DALEY
Twelve Months of Isoniazid Compared with Four Months of Isoniazid and Rifampin for Persons with Radiographic Evidence of Previous Tuberculosis . An Outcome and Cost-Effectiveness Analysis
Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1648 - 1652.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society